Annals of Oncology Advance Access originally published online on January 29, 2009
Annals of Oncology 2009 20(6):1026-1031; doi:10.1093/annonc/mdn759
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
1 Department of Medicine/Medical Oncology, Duke University Medical Center, Durham
2 Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles
3 Internal Medicine, Oncology, Florida Cancer Care, Davie
4 The West Clinic, Memphis
5 Oncology Medicine Development Center, GlaxoSmithKline, Collegeville
6 Medical Oncology/Solid Tumor Oncology, Dana Farber Cancer Institute, Boston, USA
* Correspondence to: Dr K. L. Blackwell, Department of Medicine, Division of Medical Oncology, Box 3893, Duke University Medical Center, Durham, NC 27710, USA. Tel: +1-919-668-1748; Fax: +1-919-681-0889; E-mail: black034{at}mc.duke.edu
Background: This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy.
Patients and methods: Women with stage IIIB/IV HER2-overexpressing breast cancer were treated with single-agent lapatinib 1250 or 1500 mg once daily after protocol amendment. Tumor response according to RECIST was assessed every 8 weeks. HER2 expression was assessed in tumor tissue by immunohistochemistry and FISH.
Results: Seventy-eight patients were enrolled in the study. Investigator and independent review response rates [complete response (CR) or partial response (PR)] were 7.7% and 5.1%, and clinical benefit rates (CR, PR, or stable disease for 
24 weeks) were 14.1% and 9.0%, respectively. Median time to progression was 15.3 weeks by independent review, and median overall survival was 79 weeks. The most common treatment-related adverse events were rash (47%), diarrhea (46%), nausea (31%), and fatigue (18%).
Conclusions: Single-agent lapatinib has clinical activity with manageable toxic effects in HER2-overexpressing breast cancer that progressed on trastuzumab-containing therapy. Studies of lapatinib-based combination regimens with chemotherapy and other targeted therapies in metastatic and earlier stages of breast cancer are warranted.
Key words: EGFR, ErbB1, ErbB2, lapatinib, tyrosine kinase inhibitor
Received for publication July 16, 2008. Revision received November 7, 2008. Accepted for publication November 10, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Johnston, J. Pippen Jr, X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, et al. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer J. Clin. Oncol., November 20, 2009; 27(33): 5538 - 5546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pretorius, X.-J. Du, E. A. Woodcock, H. Kiriazis, R. C.Y. Lin, S. Marasco, R. L. Medcalf, Z. Ming, G. A. Head, J. W. Tan, et al. Reduced Phosphoinositide 3-Kinase (p110{alpha}) Activation Increases the Susceptibility to Atrial Fibrillation Am. J. Pathol., September 1, 2009; 175(3): 998 - 1009. [Abstract] [Full Text] [PDF]
|
|